Conference Call with Gland Pharma Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Gland Pharma announced Q1FY25 results: Consolidated revenue surged 16% YoY to Rs 14,017 million. Consolidated EBITDA decreased 11% YoY to Rs 2,654 million. Consolidated EBITDA margin was at 19% versus 25% in Q1FY24. Base business (ex-Cenexi) revenue grew 14% YoY to Rs 10,134 million. Base business (ex-Cenexi) EBITDA jumped 12% YoY to Rs 2,941 million. Base business (ex-Cenexi) EBITDA margin was at 29% versus 30% in Q1FY24. Commenting on the results, Srinivas Sadu, Executive Chairman and CEO of Gland Pharma, said, “We reached Rs 14,017 million in total revenue, a 16% increase from Q1FY24. This growth aligns with our projections and is primarily driven by the US market, which saw a 27% revenue increase led by existing and certain new products. Our base business EBITDA margins were at 29%, and consolidated EBITDA margins for the quarter were 19%, mainly affected by Cenexi. We're confident in our ability to meet our fiscal year goals and are excited about the growing opportunities and even stronger results expected in the coming quarters.” Result PDF